Eli Lilly

LLYPre-clinical

Eli Lilly is one of the world's largest pharmaceutical companies with over 145 years of experience in developing life-changing medicines. The company has achieved significant recent success with GLP-1 receptor agonists for diabetes and weight management, generating substantial revenue growth. Lilly continues to invest heavily in R&D across key therapeutic areas including diabetes, oncology, autoimmune diseases, and neurodegeneration, with a robust pipeline of innovative treatments in development.

Market Cap

$5.5B

Employees

35,000-40,000

Focus

AntibodiesBiologicsRNA & Gene Therapy

LLY · Stock Price

USD 14.382.81 (-16.36%)

Historical price data

AI Company Overview

Technology Platform

Multi-platform pharmaceutical company with capabilities in biologics, small molecules, protein engineering, and precision medicine approaches across major therapeutic areas.

Pipeline Snapshot

1000

1000 drugs in pipeline, 685 in Phase 3

Drug	Indication	Stage
Intramuscular Olanzapine Depot + Oral Olanzapine	Schizophrenic Disorders	Phase 3
Placebo + Lebrikizumab + Topical Corticosteroid	Atopic Dermatitis	Phase 3
gemcitabine + Cisplatin	Non-Small Cell Lung Cancer	Phase 3
Orforglipron + Insulin Glargine	Type 2 Diabetes	Phase 3
high dose FDC + BI 10773 high dose + high dose FDC placebo + low dose FDC placebo + high dose FDC placebo + high dose FDC placebo + low dose FDC placebo + low dose FDC placebo + high dose BI 10773 placebo + low dose FDC + high dose FDC placebo + BI 10773 low dose + high dose BI 10773 placebo + high dose BI 10773 placebo + linagliptin + low dose FDC placebo + linagliptin placebo + BI 10773 low dose placebo + linagliptin placebo + low dose BI 10773 placebo + linagliptin placebo + high dose BI 10773 placebo + BI 10773 low dose placebo + low dose BI 10773 placebo + linagliptin placebo	Diabetes Mellitus, Type 2	Phase 3

FDA Approved Drugs

INLURIYONDASep 25, 2025

EBGLYSSBLASep 13, 2024

KISUNLABLAJul 2, 2024

Opportunities

Significant growth potential from expanding tirzepatide franchise across obesity and diabetes indications, potential breakthrough in Alzheimer's disease with donanemab, and robust pipeline advancement across high-value therapeutic areas.

Risk Factors

Patent cliff risks for mature products, intense competition in diabetes market from Novo Nordisk and others, regulatory uncertainties for Alzheimer's treatments, and potential pricing pressures from healthcare cost containment initiatives.

Competitive Landscape

Competes with Novo Nordisk and Sanofi in diabetes, Roche and Bristol Myers Squibb in oncology, and AbbVie in immunology. Differentiated by leading GLP-1 franchise, strong Alzheimer's program, and comprehensive global infrastructure.

Publications

Pipeline

1000

FDA Approvals